Vulnerable population - Paediatric medicinal products

The introduction of the Paediatric Investigation Plan (PIP) will be accompanied by measures designed to improve the supply of medicines to children and adolescents by making paediatric uses a standard part of the development programme of new medicinal products. The requirements pertaining to the PIP are harmonised with corresponding requirements in other countries, particularly in the EU (PIP).

The protection of the documentation and data arising from the development of medicinal products will be extended to create incentives for making medicines available to vulnerable populations as well..

Last modification 03.05.2018

Top of page